search
Back to results

Safety Evaluation of Telmisartan Plus Hydrochlorothiazide in Patients With Mild-to-Moderate Hypertension

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Telmisartan/hydrochlorothiazide
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • All patients who were randomized and completed all study visits of the preceding double-blind trial with the fixed dose combination (502.261) who meet the following criteria:

    • Patients that are not controlled on telmisartan 80 mg monotherapy at the final visit (Visit 6) of the 502.261 study
  • Patients who are able to provide written informed consent
  • Patients who are able to enter the study immediately upon their completion of the preceding double-blind trial of the fixed dose combination (502.261)

Exclusion Criteria:

  • Patients with any exclusion criterion (except criteria 1, 19 and 20), as defined in the preceding study (502.261):

    • Pre-menopausal women (last menstruation ≤ 1 year prior to start of screening)

      • who are not surgically sterile (hysterectomy, tubal ligation)
      • who are NOT practicing acceptable means of birth control or who do NOT plan to continue using an acceptable method throughout the study. Acceptable methods of birth control include intrauterine device (IUD), oral, implantable or injectable contraceptives
    • Any women:

      • who has a positive serum pregnancy test at screening (Visit 1) or baseline (Visit 4)
      • who has a positive urine pregnancy test prior to taking the first dose of open-label medication (at Visit 2)
      • who is nursing
    • Hepatic and/or renal dysfunction as defined by the following laboratory parameters:

      • SGPT (ALT) (serum glutamate pyruvate transaminase) or SGOT (AST) (serum glutamate oxaloacetate transaminase) greater than two times the upper limit of normal
      • Serum creatinine > 2.3 mg/dL
    • Clinically relevant sodium depletion, hyperkalemia, or hypokalemia at baseline
    • Known or suspected secondary hypertension
    • Bilateral renal artery stenosis; renal artery stenosis in a solitary kidney; post-renal transplant patients, presence of only one functioning kidney
    • Congestive heart failure (CHF) (NYHA (New York Heart Association) class CHF III-IV)
    • Unstable angina within the past three months
    • Stroke within the past six months
    • Myocardial infarction or cardiac surgery within the past three months
    • PTCA (percutaneous transluminal coronary angioplasty) within the past three months
    • History of angioedema
    • Sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator
    • Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of the aortic or mitral valve
    • Administration of digoxin or other digitalis-type drugs
    • Patients with insulin treated Type II diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an HbA1C ≥ 10%
    • Known drug or alcohol dependency within the past one year period
    • Known hypersensitivity to any component of the formulations
    • Any clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of trial medication

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    Telmisartan + Hydrochlorothiazide

    Arm Description

    Outcomes

    Primary Outcome Measures

    Incidence of adverse events
    Changes from baseline in laboratory tests
    Changes from baseline in physical examination
    Changes from baseline in 12-lead ECG (electrocardiogram)
    Changes from baseline in seated blood pressure
    Changes from baseline in pulse rate

    Secondary Outcome Measures

    Full Information

    First Posted
    June 26, 2014
    Last Updated
    July 7, 2014
    Sponsor
    Boehringer Ingelheim
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02177487
    Brief Title
    Safety Evaluation of Telmisartan Plus Hydrochlorothiazide in Patients With Mild-to-Moderate Hypertension
    Official Title
    An Open-Label, Six Month Safety Evaluation of the Fixed Dose Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg in Patients With Mild-to-Moderate Hypertension
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2014
    Overall Recruitment Status
    Completed
    Study Start Date
    June 1999 (undefined)
    Primary Completion Date
    January 2000 (Actual)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Boehringer Ingelheim

    4. Oversight

    5. Study Description

    Brief Summary
    Study to assess the safety of six month of open-label, treatment with the fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 12.5 mg in a subset of patients with mild-to-moderate hypertension who completed the eight week randomized, double blind 502.261 study.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Hypertension

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    100 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Telmisartan + Hydrochlorothiazide
    Arm Type
    Experimental
    Intervention Type
    Drug
    Intervention Name(s)
    Telmisartan/hydrochlorothiazide
    Primary Outcome Measure Information:
    Title
    Incidence of adverse events
    Time Frame
    up to 6 months
    Title
    Changes from baseline in laboratory tests
    Time Frame
    Baseline and month 6
    Title
    Changes from baseline in physical examination
    Time Frame
    Baseline and month 6
    Title
    Changes from baseline in 12-lead ECG (electrocardiogram)
    Time Frame
    Baseline and month 6
    Title
    Changes from baseline in seated blood pressure
    Time Frame
    Baseline, month 1, 3 and 6
    Title
    Changes from baseline in pulse rate
    Time Frame
    Baseline, month 1, 3 and 6

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    80 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: All patients who were randomized and completed all study visits of the preceding double-blind trial with the fixed dose combination (502.261) who meet the following criteria: Patients that are not controlled on telmisartan 80 mg monotherapy at the final visit (Visit 6) of the 502.261 study Patients who are able to provide written informed consent Patients who are able to enter the study immediately upon their completion of the preceding double-blind trial of the fixed dose combination (502.261) Exclusion Criteria: Patients with any exclusion criterion (except criteria 1, 19 and 20), as defined in the preceding study (502.261): Pre-menopausal women (last menstruation ≤ 1 year prior to start of screening) who are not surgically sterile (hysterectomy, tubal ligation) who are NOT practicing acceptable means of birth control or who do NOT plan to continue using an acceptable method throughout the study. Acceptable methods of birth control include intrauterine device (IUD), oral, implantable or injectable contraceptives Any women: who has a positive serum pregnancy test at screening (Visit 1) or baseline (Visit 4) who has a positive urine pregnancy test prior to taking the first dose of open-label medication (at Visit 2) who is nursing Hepatic and/or renal dysfunction as defined by the following laboratory parameters: SGPT (ALT) (serum glutamate pyruvate transaminase) or SGOT (AST) (serum glutamate oxaloacetate transaminase) greater than two times the upper limit of normal Serum creatinine > 2.3 mg/dL Clinically relevant sodium depletion, hyperkalemia, or hypokalemia at baseline Known or suspected secondary hypertension Bilateral renal artery stenosis; renal artery stenosis in a solitary kidney; post-renal transplant patients, presence of only one functioning kidney Congestive heart failure (CHF) (NYHA (New York Heart Association) class CHF III-IV) Unstable angina within the past three months Stroke within the past six months Myocardial infarction or cardiac surgery within the past three months PTCA (percutaneous transluminal coronary angioplasty) within the past three months History of angioedema Sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of the aortic or mitral valve Administration of digoxin or other digitalis-type drugs Patients with insulin treated Type II diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an HbA1C ≥ 10% Known drug or alcohol dependency within the past one year period Known hypersensitivity to any component of the formulations Any clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of trial medication

    12. IPD Sharing Statement

    Links:
    URL
    http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/502/502.321_U00-3241.pdf
    Description
    Related Info

    Learn more about this trial

    Safety Evaluation of Telmisartan Plus Hydrochlorothiazide in Patients With Mild-to-Moderate Hypertension

    We'll reach out to this number within 24 hrs